Trevi Pharma - Bathi resik saben saham (EPS TTM) TRVI

Trevi Therapeutics management focuses on developing neurological drugs, demonstrating high scientific expertise during capital raising. The distribution of TTM net income per share visualizes the business's resilience to external shocks, where -0.40 characterizes this valuation parameter. Strategic success depends on FDA approval of proprietary cough treatments, while the environmental footprint is limited to laboratory safety standards.
Rincian analitis perusahaan Trevi Pharma (TRVI)

Trevi Therapeutics' development of the patented drug Nalbuphine ER for the therapy of severe respiratory symptoms requires significant capital expenditures, which directly impacts current profitability. The company's rolling annual per-share profit trend aggregates the net financial result over the last twelve months, adjusting it daily for the cost of capital and share volume to provide an objective assessment of the business's fundamental value.